What is a key advantage of rNPV over NPV in pharmaceutical valuation?

Question

BlackTom AI · Accepted Answer

rNPV applies success probabilities to future project cash flows, so it directly captures how risk and expected value change as a drug moves through development stages.

1) Relevant concepts
- NPV (Net Present Value): sum of projected cash flows discounted to present value at a chosen discount rate.
- Probability-adjusted NPV (rNPV): multiplies each future cash flow by the probability that the project reaches that cash flow (probability of success), then discounts. This is essentially the expected present value accounting for technical and regulatory risk that declines as development progresses.

2) Step-by-step reasoning
- In pharmaceuticals, the chance of ultimate commercialization is low early (preclinical) and increases after successful trials. NPV treats cash flows as certain; rNPV reduces each cash flow by the likelihood the program survives to generate it.
- Thus rNPV produces a value profile that rises as an asset successfully clears stages (because conditional probabilities for remaining milestones increase), reflecting reduced uncertainty.

3) Numerical illustration (intermediate steps)
- Suppose projected revenue at launch in year 5 = $100M. Discount rate = 10%. Probability of success today = 30%.
- NPV (ignoring risk): 100 / (1.1^5) = 100 / 1.61051 = $62.10M.
- rNPV: Expected payoff = 100 * 0.30 = $30M; discounted: 30 / 1.61051 = $18.63M.
- If after phase II probability rises to 70% and the program reaches that stage, rNPV (from that point) becomes 100*0.70/1.61051 = $43.44M — demonstrating value increases as risk falls.

4) Why the correct answer is correct
- The calculation method shows rNPV explicitly models decreasing risk and changing expected value as assets advance. That is its key advantage over plain NPV for drug development.

5) Why other options are incorrect
- “rNPV is simpler to calculate”: false — it requires estimating stage-specific probabilities, so it’s more complex.
- “rNPV requires less data”: false — it needs additional data (probabilities of success, stage transitions).
- “rNPV always produces higher valuations”: false — rNPV is often lower than unadjusted NPV because it discounts for failure risk; it only increases relative to prior rNPV as stage-specific probabilities improve.

6) Conclusion
The correct answer is: rNPV better reflects the decreasing risk and changing value as an asset advance through development stages (matches the provided answer).

What is a key advantage of rNPV over NPV in pharmaceutical valuation?Single choice

Similar Questions

What is the primary difference between NPV and rNPV methodologies?

Is the following statement true or false? In the products of methylation-hydrolysis, every -OH group corresponds to the position of a glycosidic bond in the starting polysaccharide.

Which of the follwoing structures represents amylopectin?

Which of the following is true about an aldopentose?I. It is a monosaccharide.II. It contains a CHO groupIII. It is a disaccharide.IV. It is an oligosaccharide.

For stock A, we have 𝛽 𝑖 = 0.70. Suppose the expected market risk premium next year is 9% and the risk-free rate is 3%. What is the expected return of this stock based on the CAPM? (Please answer in % and round to 2 decimal places. If the answer is 8.057%, then in the box, write 8.06)

More Practical Tools for Students Powered by AI Study Helper

Homework AI Solver

Stylized AI Paper Writer

Plagiarism Checker Assistant

Citation AI Academic Writing Tool

In-Class Translation Assistant

AI Note Generator

AI Quiz Answers

Past Exam Questions from University Test Bank

Smart Practice Assistant

Adaptive Practice

Making Your Study Simpler